Bremelanotide (PT-141) is a synthetic peptide FDA-approved under the brand name Vyleesi to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. It functions as a melanocortin receptor agonist, acting directly on the central nervous system to increase sexual desire and arousal. Common side effects include nausea, flushing, and injection site reactions.
Key Details About PT-141 (Bremelanotide):
- Purpose: Primarily used for treating generalized, acquired low sexual desire (HSDD) in premenopausal women. It has also been used off-label for erectile dysfunction (ED) in men.
- Mechanism:Acts as a melanocortin receptor agonist (specifically MC3R and MC4R) in the brain, which affects libido.
- Administration: Administered as a subcutaneous injection in the thigh or abdomen, usually at least 45 minutes before anticipated sexual activity.
- Side Effects: The most common side effects are nausea, flushing, minor headache, and injection site irritation.
- Contraindications: It should not be used by individuals with uncontrolled high blood pressure or cardiovascular disease.
- Effectiveness: Studies show it can increase sexual desire and reduce distress related to low libido.
Unlike PDE5 inhibitors (like Viagra), which act on the vascular system, PT-141 acts on the nervous system to drastically increase desire (and erections for men).
